citalopram orion 20mg potahovaná tableta
orion corporation, espoo array - 10628 citalopram-hydrobromid - potahovaná tableta - 20mg - citalopram
dilizolen 2mg/ml infuzní roztok
glenmark pharmaceuticals s.r.o., praha ČeskÁ republika - 15392 linezolid - infuzní roztok - 2mg/ml - linezolid
linezolid kabi 2mg/ml infuzní roztok
fresenius kabi s.r.o., praha array - 15392 linezolid - infuzní roztok - 2mg/ml - linezolid
linezolid krka 2mg/ml infuzní roztok
krka, d.d., novo mesto, novo mesto array - 15392 linezolid - infuzní roztok - 2mg/ml - linezolid
linezolid mylan 600mg potahovaná tableta
mylan ireland limited, dublin array - 15392 linezolid - potahovaná tableta - 600mg - linezolid
linezolid olikla 2mg/ml infuzní roztok
olikla s.r.o., kostelec nad Černými lesy array - 15392 linezolid - infuzní roztok - 2mg/ml - linezolid
linezolid sandoz 600mg potahovaná tableta
sandoz s.r.o., praha array - 15392 linezolid - potahovaná tableta - 600mg - linezolid
methylthioninium chloride proveblue
provepharm sas - methylthioniniumchloridu - methemoglobinemie - všechny ostatní terapeutické přípravky - akutní symptomatická léčba methemoglobinemie vyvolané léčivými a chemickými produkty. methylthioninium chloride proveblue je indikován u dospělých, dětí a dospívajících (ve věku 0 až 17 let).
zydelig
gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.
tukysa
seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastická činidla - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.